Investigating immune responses to a flu vaccine
Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)
This study tests how healthy people’s immune systems respond to a flu vaccine to see if it can help protect them better in the long run.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 18 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Trial ID | NCT04080245 on ClinicalTrials.gov |
What this trial studies
This study examines the immune response of healthy individuals to the Live Attenuated Influenza Vaccine (LAIV) and its potential as a biomarker for long-lasting antibody responses. Participants will receive the LAIV and their immune responses will be assessed, followed by an intramuscular influenza vaccination to evaluate if the initial LAIV provides protective immunity. The research aims to identify specific B cell populations that may indicate effective immune protection after vaccination.
Who should consider this trial
Good fit: Ideal candidates are healthy individuals who have not received a flu vaccine in the past year and do not have a history of reactive airway disease or allergies to the vaccines.
Not a fit: Patients with a history of reactive airway disease, allergies to LAIV or IIV, or those who do not self-identify as healthy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify biomarkers that predict long-term immunity to influenza, improving vaccination strategies.
How similar studies have performed: While this approach is novel in its specific focus on T-bet expressing B cells, previous studies have shown success in identifying immune responses to influenza vaccines.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Missed getting the flu vaccine in the last year * No history of reactive airway disease * No history of allergy to LAIV * No history of allergy to IIV * Self-identify as healthy without an immunocompromising condition defined as cancer, autoimmune disease, organ transplant or receipt of steroids. Exclusion Criteria: * History of reactive airway disease * History of allergy to LAIV or IIV * Do not self-identify as healthy
Where this trial is running
Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama, United States (Recruiting)
Study contacts
- Principal investigator: Anoma Nellore, MD — University of Alabama at Birmingham
- Study coordinator: Anoma Nellore, MD
- Email: anellore@uabmc.edu
- Phone: 2059345191
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.